Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients

Phase 2 Unknown 100 enrolled The First Affiliated Hospital with Nanjing Medical University

RandomizedParallel-groupOpen-labelTreatment

Summary

This clinical trial is a multicenter, randomized, open-label, phase-II study to evaluate the efficacy and safety of maintenance treatment with eribulin mesylate following standard adjuvant chemotherapy in triple negative breast cancer patients.

Timeline

Start: 2021-06
Primary completion: 2023-06
Completion: 2024-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Eribulin	Small molecule	1.4 mg/m2	Intravenous

Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients

Summary

Timeline

Drugs

Indications